The First DNA Medicine Approved in America Works for 7 of 26 Patients

The first DNA medicine approved in the United States does not work for most of the patients it was tested on.

Voceryq, Inovio's plasmid DNA immunotherapy, won accelerated approval on 30 October 2026 to reduce how often adults with recurrent respiratory papillomatosis (RRP) go under the knife. Seven of the 26 efficacy patients needed no surgery for a full year. That is 27%, with a 95% confidence interval running from 12% to 48%.

Inovio is a 43-year-old company with no prior approved product. The FDA's own acceptance letter had questioned whether evidence this thin qualified for the accelerated pathway at all. The agency approved anyway, on the PDUFA date it had set ten months earlier.

Both facts are true at once. That is the story.

Why the endpoint was surgery, not cure

RRP is caused by HPV types 6 and 11. Wart-like growths form on the vocal cords and elsewhere in the airway. Surgery removes them; the virus stays. Patients come back, sometimes every few months, and each procedure carries a risk of scarring the voice box.

There is no cure. There is a surgical burden, and the burden is the disease.

Voceryq attacks the infected cells instead. Two plasmids go into muscle, one coding for HPV proteins and one for IL-12, an immune stimulant. A device called CELLECTRA 5PSP delivers brief electrical pulses that open pores in cell membranes so the DNA gets inside. The dosing regimen runs nine weeks, starting after a standard surgical debulking.

The trial enrolled 32 adults who had needed at least two surgeries in the prior year. The primary read was complete response: no surgical excision of papillomas for 12 months. Seven of the 26 patients with three or more baseline surgeries cleared that bar. The median patient had 4.5 surgeries in the year before treatment.

Looser measures look better. Twenty-six of 32 participants, 81%, had at least one fewer surgery. Twenty-three, or 72%, cut their surgery count by half or more. Those numbers come from the RRP-001 readout as reported by Regulatory News, and they describe a real reduction in operating-room time for most patients.

Does a 27% complete response justify a first-in-class label? The FDA decided it does, with conditions attached.

The conditions are the part to read closely. Voceryq is approved on an intermediate endpoint, reasonably likely to predict benefit, not on verified long-term benefit. The approval letter spells out what happens next.

CHRONICLE: Inovio and the DNA medicine bet
────────────────────────────────────────────
1983  ·  🏭  Inovio founded outside Philadelphia
2020  ·  ⚠️  COVID DNA vaccine hits a clinical hold over its delivery device
2021  ·  🇧🇷  Late-stage COVID work moves abroad after US funding is pulled
2025  ·  📄  BLA for INO-3107 accepted; FDA flags accelerated-pathway doubts
2026  ·  ✅  Voceryq approved for RRP on 30 October
◉ NOW   ·  Draft confirmatory protocol due 30 December 2026
🔥 NEXT ·  Full launch targeted for Q1 2027

The 2020 episode is the reason this approval reads as a comeback. Inovio's COVID vaccine, INO-4800, was put on a partial clinical hold while regulators asked questions about the CELLECTRA device used to deliver it. The US government later pulled funding for the late-stage study, and Inovio ran the Phase 3 abroad. The platform that finally cleared the FDA is the same platform, with a better-controlled indication.

That history cuts both ways. A delivery technology that once triggered a hold is now part of an approved product, which validates the engineering. It also means the company has spent four decades learning how narrow the path is.

The second entrant problem

Voceryq is not the first therapy for RRP. Precigen's Papzimeos received full approval in August 2025, with 18 of 35 patients, 51.4%, achieving complete response in its pivotal study. That approval came without a confirmatory-trial obligation.

The comparison is uncomfortable. Papzimeos cleared a higher bar, on a larger efficacy cohort, and carries an unconditional label. Voceryq enters fourteen months later as the option with the thinner file and the conditional status.

FDA approval announcements, 2025 and 2026; efficacy definitions differ between the two single-arm studies.

Inovio's counter-argument is market size and eligibility. The company estimates at least 25,000 prevalent US patients, based on claims data, and its label covers patients with two or more prior surgeries. Paper logic says both products can grow into a population that has had almost no medical options.

Commercial logic says the second entrant has to justify a switch. Surgery is familiar, reimbursed, and available everywhere. A nine-week regimen with a proprietary delivery device is not.

What the FDA now requires

The approval letter is unusually specific. Inovio must run a confirmatory study of at least 50 adults and pediatric patients with three or more prior surgeries, follow them for at least three years, and compare outcomes against an appropriate external control or a justified threshold. The draft protocol is due 30 December 2026. The final protocol is due 30 June 2027. Study completion is dated 30 December 2031, with the final report in August 2032.

“Adults living with recurrent respiratory papillomatosis often face an exhausting and relentless cycle of repeated surgeries, managing their disease, but never truly escaping it.”— Karim Mikhail, Director, FDA Center for Biologics Evaluation and Research

Dr. Simon Best, an otolaryngologist at Johns Hopkins and a lead investigator on RRP-001, framed the benefit in the same register: every surgery carries a risk of laryngeal injury. That is the clinical case for a therapy that reduces frequency without eliminating the procedure.

What to watch before the launch

Inovio says Voceryq will be available to order and ship in roughly 60 days, with full field deployment in the first quarter of 2027. Syneos Health has been engaged to recruit and deploy the medical and commercial teams. The drug product is made by Alliance Medical Products, operating as Siegfried, in Irvine, California. The CELLECTRA device is made in San Diego.

Three dates matter more than the launch date. The first is 30 December 2026, when the draft confirmatory protocol lands. Its design, controlled or single-arm, will tell you how confident the company is. The second is the first full quarter of sales, which will show whether physicians switch from a fully approved product. The third is the confirmatory readout, years out, which decides whether this approval becomes permanent.

Approval is a regulatory event, not a commercial one. As we wrote in October, Hanmi's first homegrown GLP-1 approval moved its stock down 6% on the day. Markets have learned to price the difference between a first approval and a first revenue line.

The DNA medicine era in the US now has a start date. It begins with a conditional approval, a 27% complete response, and a confirmatory trial that will not report for years. That is a genuine first. It is also a bet the company has to keep winning.